Versant Ventures

Website Links

Description

Versant Ventures is a leading venture capital firm specializing in investments in game-changing biopharmaceutical and medical device opportunities. Versant pioneered the build-to-buy structured exit model, creating new companies based on insights and knowledge from the pharmaceutical and biotechnology industries. Founded in 1999, the firm consists of an experienced team of investors committed to helping entrepreneurs build successful companies that are developing breakthrough therapies for debilitating diseases. Versant has offices in the US, Canada and Switzerland.

Versant Ventures has a team in Basel, Switzerland, dedicated to working with entrepreneurs, industry and leading academics across Europe.The team has decades of experience in the pharmaceutical and biotechnology industries, including global roles in drug discovery, research and product development for companies such as Roche, Novartis and Lilly. Versant's Basel office is led by Tom Woiwode , Guido Magni , Gianni Gromo and Carlo Rizutto .

Before joining CrossPoint, Don was CEO of Infusion Systems Corporation, a CrossPoint portfolio company. He also served as president of TRIMED Corporation, a manufacturer of dialysis, hemophilia and IV products. Additionally, he held business development positions with Eastman Kodak and Dynatech. As one of the pioneer venture investors in healthcare services, Don developed a highly successful model for early-stage investing in the sector.

Steve is a San Diego-based Venture Partner with Versant Ventures and is also the CEO of Quanticel Pharmaceuticals, a privately held Versant portfolio company focused on cancer drug discovery.

Pharmion is an emerging pharmaceutical company focused on marketing drugs that require specialized medical education and marketing programs. The company’s initial focus is on drugs currently marketed for the treatment of cancer and related diseases for markets in the US, as well as in Europe and other major international markets. Celgene aquired Pharmion for $2.9 billion March 2008.

Fact sheet

Company contacts

Companies nearby